Physician profile
Thomas Vertrees
NPI 1356524839
$2,868.44
in general payments reported to CMS, 2019-2025
15 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $389 · 2024: $1,404 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,868.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $523.37 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $477.81 | 2023-2025 | Caplyta |
| Abbvie INC. | $329.79 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $320.83 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $185.61 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $181.66 | 2024-2025 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $156.60 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $137.07 | 2024-2025 | Ingrezza |
| Noven Therapeutics, LLC | $125.51 | 2024-2025 | Xelstrym, Secuado |
| Janssen Pharmaceuticals, INC | $113.38 | 2024-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $89.08 | 2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $83.94 | 2025 | Auvelity |
| Lundbeck LLC | $56.27 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $47.83 | 2024-2025 | Qelbree |
| Tris Pharma INC | $39.69 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vertrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.